Cannabis Law Report

AUGUST 10, 2021

This authorisation for TSC, represents the fourth approved indication of a cannabis-based medicine in the UK for GW and underlines GW’s commitment to the UK and regulatory approved cannabis-based medicines. “We GW’s pioneering work has led to the regulatory approval of world first, potentially life changing, cannabis-based medicines.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

JUNE 23, 2021

COPENHAGEN , June 22, 2021 /PRNewswire/ — Valcon Medical A/S (“Valcon Medical” or the “Company”), Denmark’s leading independent cannabis concentrate and medical formulation provider, received its licensing for the commercial production of cannabis from the Danish Medicines Agency (DKMA) earlier in May 2021.

Pharmaceutical 86

Pharmaceutical Concentrates Extraction Medicine 86

Veriheal

JULY 26, 2023

Georgia medical cannabis patients will soon have greater access to treatment as cannabis oil will be sold in many more pharmacies. The Georgia State Board of Pharmacy recently made the decision to endorse more cannabis oil sale outlets. Eligible patients were granted access to low-THC marijuana oil.

Oil 98

Oil Patients Access THC 98

Cannabis Law Report

DECEMBER 15, 2021

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC ) has entered into an agreement to divest its subsidiary business, C³ Cannabinoid Compound Company GmbH (“C3”), to Dermapharm Holding SE (“Dermapharm”) (WKN: A2GS5D, ISIN: DE000A2GS5D8), a European pharmaceutical company headquartered in Grünwald, Germany.

Pharmaceutical 52

Pharmaceutical Cannabinoids Business Extraction 52

Cannabis Law Report

AUGUST 22, 2021

“Looking at the industry as it is growing, we are seeing the emergence of a brand-new sector: the psycheceutical industry, which merges the best of psychedelics and the best of pharmaceuticals. . is using cutting-edge delivery technologies to develop safe and effective psychedelic pharmaceutical medicines. Psycheceutical, Inc.

Pharmaceutical 98

Pharmaceutical Medicine Research and Development Therapy 98

Veriheal

JUNE 22, 2021

“Cannabis should remain illegal because more research is needed. We are not fully aware of the consequences of cannabis legalization because there are not enough studies to solidify its therapeutic uses” Yet the same individuals spewing this crap are the ones that stand in the way of progress.

DEA 60

DEA Access Therapy Cannabinoids 60

CannaTech

JANUARY 16, 2019

Thanks to the recent emergence of regulated medical cannabis markets, the success of this versatile plant can be followed from farm to pharma and prescriber to patient, however, the origins of cannabis as medicine cannot be as simply traced as the plant is today from seed to sale. It is not a story about profiting off of people.

Access 89

Access Patients Pharmaceutical Education 89

Cannabis Law Report

JULY 5, 2021

The management of a cannabis company is very complex and needs support as more detailed. Access Control. Since the ERP is equipped with all of the company’s information, the access to data is controlled. and each user can only access part of the information. Cannabis Stock Control. There are other. accounting.

Pharmaceutical 111

Pharmaceutical Data Access Business 111

Cannabis Law Report

NOVEMBER 10, 2019

Europe Cannabis and Pain Management Devices on Cancer Pain Market Report 2019 is dispensed after a thorough study of various key market segments such as market size, latest trends, market threats and key drivers driving the Europe Cannabis and Pain Management Devices on Cancer Pain market. UNIMED PHARMACEUTICALS.

Pharmaceutical 45

Pharmaceutical Research and Development Data Business 45

Cannabis Law Report

DECEMBER 8, 2021

Global Psychiatry Partnering 2014 to 2021 provides the full collection of Psychiatry disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Access to headline, upfront, milestone and royalty data. Access to hundreds of Psychiatry deal contract documents. Accera Pharmaceuticals.

Access 52

Access Data Pharmaceutical Research and Development 52

Cannabis Law Report

JUNE 1, 2022

This acquisition will accelerate Khiron’s growth in Europe by controlling the complete value chain for its products and gaining direct access to German pharmacies. Pharmadrug GmbH has been active worldwide for almost 40 years as a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients.

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

SpeedWeed

APRIL 9, 2021

Nearly two-thirds of Texas medical cannabis users said that weed helped them quit using opioids, benzodiazepines, and other prescription medicines, a new survey reports. From August 11th to October 6th, 2020, researchers asked Texas residents who were using cannabis medicinally to answer an anonymous online survey. percent THC content.

Pharmaceutical 52

Pharmaceutical Chronic Pain Programs Patients 52

Veriheal

SEPTEMBER 16, 2020

Though cannabis is becoming increasingly legal across the nation, both for recreational and medical purposes, there’s no sign that the US government intends to legalize cannabis on the federal level. This causes complications as more people than ever before are exploring cannabis for medical purposes. What is Epidiolex?

Access 98

Access Epilepsy Treatment Conditions 98

Cannabis Law Report

JANUARY 4, 2022

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Unfortunately, this number is expected to increase rapidly with legalized marijuana and access to substances that have five times the THC concentration of regular marijuana,” said Mr. Allen. “We About Anebulo Pharmaceuticals, Inc. and Australia.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Cannabis Law Report

SEPTEMBER 22, 2022

List Medicinal Cannabis on the PBS. The Federal Parliament legalised the use of medicinal cannabis products in Australia in February 2016, but access to treatment is still severely limited due to cost, with patients reporting average monthly costs in excess of $300 , or approximately $10 per day. He writes on his website.

Pharmaceutical 52

Pharmaceutical Media Medicine Treatment 52

Cannabis Law Report

SEPTEMBER 22, 2021

Exclusive licensing agreement with leading global cannabis company (“Canopy Growth”). Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. As Canopy Growth remains focused on commercialisation, this agreement will grant OCT access to the Canopy Library to advance this research.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

NORML

JULY 1, 2019

Three new laws intended to expand patient access to and the therapeutic value of Virginia’s medical cannabis program take effect July 1, 2019. “These bills help ensure that all patients are able to obtain and use the necessary therapeutic doses of their cannabis medicines regardless of location or physical ability.”

Law 258

Law Patients Access Oil 258

Cannabis Law Report

JANUARY 6, 2022

An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. From there, former researchers working for big pharma will dictate what products are available to patients, how treatments are accessed, and cost. Threat to Patient Access in Oregon. You can contact Brett Mulligan at ?

Access 52

Access Patients Research and Development Treatment 52

Cannabis Law Report

DECEMBER 11, 2021

A Manchester MP’s bid to open up cannabis treatments on the NHS has been blocked by Tory backbenchers in the House of Commons. 'A Despite the Government legalising medicinal cannabis in 2018, following a number of high-profile campaigns, thousands of people are still being denied access to the treatment. Read more at.

Treatment 52

Treatment Access Patients Medicine 52

Cannabis Law Report

AUGUST 1, 2022

While the subject of cannabis often triggers the removal of content and banned accounts, pharmaceutical scientists Dr. Riley Kirk, PhD and Dr. Miyabe Shields, PhD are using platforms like TikTok and Instagram to help followers understand cannabis pharmacology, while gathering unique data on their experiences with it.

Education 52

Education Access Media Data 52

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. Medical cannabis costs family £4,000 a month to help teenager. What is Epidyolex?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

MMJ Recs

MARCH 23, 2024

Health Effects of Cannabis Legalization in Michigan The health effects of cannabis legalization in Michigan encompass both potential benefits and risks for residents. Legalization may offer expanded access to medical cannabis for patients suffering from various conditions, providing alternative treatment options and symptom relief.

Legalization 52

Legalization Access Programs Education 52

Cannabis Law Report

SEPTEMBER 8, 2021

Key Transaction Details: The Valens Company, a leading Canadian manufacturer of cannabis products, has entered into a long-term partnership with Epsilon, for exclusive access to the Epsilon’s GMP Manufacturing Facility in Southport , Queensland Australia (the “ Southport Facility ‘).

Access 97

Access Research and Development Medicine THC 97

Cannabis Law Report

SEPTEMBER 8, 2021

Flora will use TruTrace’s blockchain-enabled platform for seed-to-sale tracking of its cannabis products – including integration of Applied DNA’s molecular tagging technology – to offer Flora’s customers a complete product validation and authentication solution. CSE: TTT; OTCQB: TTTSF) (“TruTrace”) and Applied DNA Sciences, Inc.

Supply Chain 95

Supply Chain Pharmaceutical Seed-To-Sale Events 95

Cannabis Life Network

MARCH 30, 2023

Decriminalizing small amounts of opioids, cocaine, meth, and ecstasy is designed to “help reduce the barriers and stigma that prevent people from accessing life-saving supports and services.” appeared first on Cannabis | Weed | Marijuana | News. Now they’re ready to profit from “safe supply.”

Decriminalization 92

Decriminalization Pharmaceutical Access Marijuana 92

Cannabis Law Report

FEBRUARY 7, 2023

Under this new program, Protonify will provide cannabis researchers with complimentary access to its high-purity, pharmaceutical-grade cannabinoid ingredients including THC concentrate and THCA isolate.

Pharmaceutical 52

Pharmaceutical Cannabinoids Concentrates THC 52

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. The live webcast can be accessed here and on the investor page of Marinus’ website. About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc. RADNOR, Pa.–(BUSINESS 484-253-6792.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

The Fresh Toast

AUGUST 19, 2019

With the stigma of cannabis fading by the day, more families are exploring treatments that are more accessible and less pharmaceutical. Continue reading The Potential Of CBD And Cannabis Within The Anxiety And Autism Community at The Fresh Toast.

CBD 111

CBD Pharmaceutical Treatment Access 111

The Fresh Toast

DECEMBER 21, 2021

As cannabis becomes less stigmatized, the autism community is exploring treatments that are more accessible and less pharmaceutical. THC More Effective Than CBD In Treating Autism, New Preliminary Study Shows.

THC 104

THC CBD Pharmaceutical Treatment 104

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

MGC Pharma

FEBRUARY 22, 2018

While at home in Australia, the Medical Cannabis industry is still working hard to gather more evidence-based research to substantiate treatment assertions, relevant studies are already occurring overseas. of respondents who received Medical Cannabis treatment reported improvement in their condition and significant reductions to pain levels.

Research and Development 100

Research and Development Pharmaceutical Chronic Pain Treatment 100

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Promoting Research and Innovation The medical marijuana industry promotes research and innovation in the field of cannabis-based therapies.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

NORML

MAY 26, 2020

A team of Israeli researchers conducted a randomized placebo-controlled clinical trial to assess the safety and efficacy of a novel, metered-dose cannabis inhaler in 27 patients with chronic pain. Chronic pain is the most commonly reported qualifying condition among medical cannabis patients enrolled in state-specific access programs.

Clinical Trials 250

Clinical Trials Chronic Pain Cannabinoids Patients 250

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Project CBD

JULY 28, 2023

Scialdone is a founding member of the Cannabis Chemistry Subdivision of the American Chemical Society from which he received the 2018 CANN-CHAS Heidolph Award for Excellence in Cannabis Chemistry. These are not present in cannabis and are only formed in the chemical conversion, whose impact on human health is unknown.

THC 212

THC Cannabinoids Hemp Research and Development 212